Navigation Links
EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Date:10/2/2008

priority clinical oncology programs. Listing our shares on the Nasdaq Capital Market extends our compliance period by six months, during which time we expect to make further clinical progress and will continue to pursue a development partner for our Aurora/angiogenesis program. We will also continue to explore available options for regaining compliance with Nasdaq listing requirements."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assum
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... on the current state of the Papain industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) filed ... Appeals for the D.C. Circuit challenging the FAA’s Interpretation of ... Register on June 25, 2014. , The AMA believes ... and intent of the FAA Modernization and Reform Act of ... any new rules or regulations regarding model aircraft that are ...
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... periods ended June 30, 2014.  Biorem,s complete 2014 second quarter financial statements ... Financial Summary:Three-months ended June 30, , Six-months ended ... 2014 , 2013 , 2014 , ... 4,433 , 9,195 Gross profit , 56 , ...
(Date:8/22/2014)... Surrey have discovered how the receptors responsible for contractions ... The new study, published today in The FASEB ... turn regulates the cycle of all cells in the ... local biological clock and its control are weakened in ... bladder physiology and ageing. , While currently ...
Breaking Biology Technology:Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2
... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) today ... Small and Mid Cap Growth Conference in Naples, ... 4:40 p.m. EST. Kevin,Hrusovsky, President and CEO of ... business. The live webcast can be accessed at, ...
... Candidate Represents Potential New Short-Course Treatment Option for ... Serious Gram-Positive Skin Infections, Including MRSA, CAMBRIDGE, ... TARG ) announced today that it has,submitted a ... and Drug,Administration (FDA) for its lead antibiotic candidate, ...
... PROENCY will provide real-world clinical data on the ... Boston Scientific,Corporation (NYSE: BSX ) today announced ... PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European,registry. The registry ... It will collect real-life clinical outcome data for ...
Cached Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
(Date:8/22/2014)... , August 22, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the addition ... America 2014-2018"  report to their offering.  ... , ,Biometrics is a technology that ... based on their physical or behavioral ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... at the 29th Annual International Papillomavirus Conference shows ... Inc. combats three types of human papillomavirus, including ... cervical cancer. , When tested in several cultured ... HPV-16, HPV-18 and HPV-11 cells, according to Louise ... presented the findings at the Seattle conference. The ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... University scientist Chittaranjan Kole was awarded the Outstanding Crop ... He was one of three scientists to receive the ... the field of crop science. He also chaired a ... this month, "Genomics and Breeding of Climate Resilient ...
... out of research conducted on the edge of the ... Gorge in Tanzania since that produced by Louis and ... special issue of the prestigious Journal of Human ... the Bernard Price Institute for Palaeontological Research, and Professor ...
... consumer products such as shampoos, gels, hair dyes and ... food crops, as reported in a paper in the ... of Sciences . Manufactured nanomaterials are man-made materials ... scale. Their effects on human health and the environment ...
Cached Biology News:Dawn of humanity illuminated in special journal edition 50 years after the Leakeys 2Soybeans susceptible to man-made materials in soil 2Soybeans susceptible to man-made materials in soil 3
... Simultaneously perform 96 assays on four ... four microarray slides with 96 (6mm x ... protein, gene expression, or screening analysis studies. ... compression fit gasket, eliminating the presence of ...
... is an automated multiplexing platform that uses ... pathogen sequence detection and pharmacogenetics applications. Multiple ... to an open and flexible electronic microarray, ... until all tests sites have been utilized. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
Biology Products: